Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
Condition(s) studied
Study summary
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy.
The purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.
Eligibility
Primary outcome measure(s)
- Biospecimen Retention: Samples with DNA — At 1 day of biospecimen collection
Blood samples, up to 60 mls, will be obtained according to standard operating procedures. Subjects will collect stool samples per the schedule in the study calendar. Collection of Frozen Normal and Adenoma or Cancer Tissue: For individuals with large adenomas who are undergoing endoscopic resection, the fresh surgical sample will be obtained by the endoscopist.
Trial sites (13)
| Facility | City | Region | Status |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | Recruiting |
| Carle Cancer Center | Urbana | Illinois | Completed |
| Dana Farber Cancer Institute | Boston | Massachusetts | Recruiting |
| University of Michigan | Ann Arbor | Michigan | Recruiting |
| University of Minnesota | Minneapolis | Minnesota | Recruiting |
| NYU Langone Health | New York | New York | Recruiting |
| University of North Carolina | Chapel Hill | North Carolina | Completed |
| Oregon Health and Science University | Portland | Oregon | Recruiting |
| Hershey Medical Center | Hershey | Pennsylvania | Completed |
| M.D. Anderson Cancer Center | Houston | Texas | Recruiting |
| University of Washington | Seattle | Washington | Recruiting |
| Flinders Medical Center | Adelaide | South Australia | Recruiting |
| St. Michael's Hospital | Toronto | Ontario | Withdrawn |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT00843375 on ClinicalTrials.gov ↗ ← All trials in Canada